Format

Send to

Choose Destination
Pediatr Blood Cancer. 2018 Feb;65(2). doi: 10.1002/pbc.26849. Epub 2017 Oct 27.

Irinotecan for relapsed Wilms tumor in pediatric patients: SIOP experience and review of the literature-A report from the SIOP Renal Tumor Study Group.

Author information

1
Department of Pediatric Oncology, Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
2
Department of Pediatric Oncology & Hematology, Saarland University, Homburg, Germany.
3
UCL Great Ormond Street Institute of Child Health, University College London, London, United Kingdom.
4
Department of Pediatric Hematology and Oncology, Rigshospitalet, Copenhagen, Denmark.
5
Department of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands.
6
Department of Pediatric Oncology, Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom.
7
Pediatric Oncology, La Timone Children's Hospital, Marseille, France.
8
Department of Pediatric Oncology, Institut d'Hematologie et d'Oncologie Pédiatrique, Centre Léon Bérard, Lyon, France.
9
St. Anna's Children's Hospital, Department of Pediatrics, Medical University Vienna, Vienna, Austria.
10
Pediatric Oncology Unit, Department of Hematology and Pediatric Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Abstract

While irinotecan has been studied in various pediatric solid tumors, its potential role in Wilms tumor (WT) is less clear. We evaluated response and outcome of irinotecan-containing regimens in relapsed WT and compared our results to the available literature. Among 14 evaluable patients, one complete response (CR) and two partial responses (PRs) were observed in patients with initial intermediate-risk (CR and PR) and blastemal-type histologies (PR). Two patients were alive at last follow-up showing no evidence of disease. Our results and the reviewed literature suggest some effectiveness of irinotecan in the setting of relapsed WT.

KEYWORDS:

irinotecan; pediatric solid tumors; relapsed Wilms tumor

PMID:
29077255
DOI:
10.1002/pbc.26849
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center